Active, not recruitingPhase 3NCT05270044
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Studying Germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pierre Fabre Medicament
- Principal Investigator
- Alexander C.J. van AKKOOI, MD, PhDEuropean Organisation for Research and Treatment of Cancer - EORTC
- Intervention
- Encorafenib and Binimetinib(drug)
- Enrollment
- 815 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2035
Study locations (30)
- Centro Oncologico Korben, CABA, Buenos Aires, Argentina
- Centro de Investigaciones Medicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina
- Fundacion CIDEA, Ciudad Autonoma Bs As, Ciudad Autonoma Buenos Aires, Argentina
- Sanatorio Britanico S.A., Rosario, Santa Fe Province, Argentina
- Instituto de Oncologia de Rosario, Rosario, Santa Fe Province, Argentina
- Hospital Aleman, Ciudad Autonoma Buenos Aires, Argentina
- Instituto Medico Especializado Alexander Fleming, Ciudad Autonoma Buenos Aires, Argentina
- Clinica Adventista Belgrano, Ciudad Autonoma Buenos Aires, Argentina
- Westmead Hospital, Sydney, New South Wales, Australia
- Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
- Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- Adelaide Oncology & Haematolog, Calvary North Adelaide Hospital, North Adelaide, South Australia, Australia
- Box Hill Hospital, Box Hill, Victoria, Australia
- Austin Health, Heidelberg, Victoria, Australia
- The Alfred Hospital, Prahran, Victoria, Australia
- +15 more locations on ClinicalTrials.gov
Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05270044 on ClinicalTrials.govOther trials for Germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07552233NK Cell Therapy for Malignant Solid Brain TumorsPeking University Third Hospital
- RECRUITINGNCT07314164Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentIpsen
- RECRUITINGPHASE1NCT07143812A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed GlioblastomaCHA University
- RECRUITINGNANCT06910306Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent GlioblastomaAlpha Tau Medical LTD.
- RECRUITINGNANCT07459101UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4Sunnybrook Health Sciences Centre
- RECRUITINGPHASE1, PHASE2NCT07193966NG2 and DLL3 CAR-T Cells Targeting MelanomaShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06712927Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesStanford University
- RECRUITINGPHASE1, PHASE2NCT06712875MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasAnn & Robert H Lurie Children's Hospital of Chicago